Aevi Genomic Medicine, LLC, a Cerecor company
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Aevi Genomic Medicine, LLC, a Cerecor company sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
Aevi Genomic Medicine, LLC, a Cerecor company: 10 sponsored US clinical trials, none currently recruiting.
Aevi Genomic Medicine, LLC, a Cerecor company sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Attention Deficit Disorder With Hyperactivity, with 2 trials.
Top-decile sponsor footprint
Aevi Genomic Medicine, LLC, a Cerecor company ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
10 total, page 1 of 1
Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
NCT04412057
PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations
NCT03609619
PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations
NCT03265119
A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations
NCT03233867
Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD
NCT03006367
Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions
NCT02895906
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
NCT02777931
A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD
NCT02811211
TARGTEPO Treatment for Anemia in PD US Trial
NCT02468414
Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
NCT02286817
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 5 |
How the Aevi Genomic Medicine, LLC, a Cerecor company early-phase archive is shaped
10 indexed studies, none listed as recruiting (0% open); 9 completed (90%).
Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Attention Deficit Disorder With Hyperactivity (2 trials), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Aevi Genomic Medicine, LLC, a Cerecor company: archived-pipeline peers nationwide
Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Aevi Genomic Medicine, LLC, a Cerecor company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 archived trials
- Adamas Pharmaceuticals · 10 trials · 0% recruiting
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Agouron Pharmaceuticals · 10 trials · 0% recruiting
- Aimmune Therapeutics · 10 trials · 10% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Aevi Genomic Medicine, LLC, a Cerecor company page
10 registered trials is a research-attention snapshot, not an endorsement of Aevi Genomic Medicine, LLC, a Cerecor company or any single study.
- None of Aevi Genomic Medicine, LLC, a Cerecor company's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Attention Deficit Disorder With Hyperactivity is the condition Aevi Genomic Medicine, LLC, a Cerecor company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Attention Deficit Disorder With Hyperactivity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aevi Genomic Medicine, LLC, a Cerecor company pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.